{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:26Z","timestamp":1791304346901,"version":"4.3.1"},"reference-count":20,"publisher":"American Veterinary Medical Association (AVMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"Abstract<\/jats:title>\n \n OBJECTIVE<\/jats:bold>\n To determine histologic and clinical factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and a chemotherapy protocol in which an anthracycline was alternated with lomustine.\n <\/jats:p>\n \n DESIGN<\/jats:bold>\n Retrospective case series.\n <\/jats:p>\n \n ANIMALS<\/jats:bold>\n 30 dogs with stage II splenic hemangiosarcoma.\n <\/jats:p>\n \n PROCEDURES<\/jats:bold>\n Medical records of 3 facilities were reviewed to identify dogs treated for stage II splenic hemangiosarcoma between June 2011 and October 2014. Information collected included signalment, disease staging data, whether anemia was present, date of splenectomy, chemotherapy protocol, adverse effects, and date of death or last follow-up. Histologic slides were reviewed and scored by pathologists. Associations between variables of interest and survival data were evaluated statistically.\n <\/jats:p>\n \n RESULTS<\/jats:bold>\n Median survival time for all dogs was 158 days (range, 55 to 560 days), and the 1-year survival rate was 16%. On multivariate analysis, only the histologically determined mitotic score was significantly associated with survival time. The median survival time of 292 days for dogs with a mitotic score of 0 (< 11 mitoses\/10 hpf; n = 9) was significantly longer than that for dogs with higher scores (indicating higher mitotic rates); the 1-year survival rate for these dogs was 42%.\n <\/jats:p>\n \n CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:bold>\n Results suggested that future studies should take histologic factors, particularly mitotic rate, as well as tumor stage into account when assessing treatment effects on survival time of dogs with splenic hemangiosarcoma.\n <\/jats:p>","DOI":"10.2460\/javma.251.5.559","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:24:46Z","timestamp":1503390286000},"page":"559-565","source":"Crossref","is-referenced-by-count":42,"title":["Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011\u20132014)"],"prefix":"10.2460","volume":"251","author":[{"given":"Antony S.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Rassnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela E.","family":"Frimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5326\/15473317-34-5-417","article-title":"Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993)","volume":"34","author":"Wood","year":"1998"},{"key":"ref2","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997\u20132004)","volume":"231","author":"Kim","year":"2007"},{"key":"ref3","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012)","volume":"247","author":"Wendelburg","year":"2015"},{"key":"ref4","series-title":"Small animal clinical oncology","first-page":"521","article-title":"Miscellaneous tumors. A. Hemangiosarcoma","author":"MacEwen","year":"1996"},{"key":"ref5","series-title":"Clin Cancer Res","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995"},{"key":"ref6","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana","year":"2007"},{"key":"ref7","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00266.x","article-title":"A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma","volume":"9","author":"Teske","year":"2011"},{"key":"ref8","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1939-1676.1993.tb01033.x","article-title":"Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide","volume":"7","author":"Sorenmo","year":"1993"},{"key":"ref9","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1476-5810.2003.00024.x","article-title":"Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin","volume":"1","author":"Payne","year":"2003"},{"key":"ref10","series-title":"Can Vet J","first-page":"237","article-title":"Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study","volume":"54","author":"Kahn","year":"2013"},{"key":"ref11","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5326\/JAAHA-MS-5954","article-title":"VAC protocol for treatment of dogs with stage III hemangiosarcoma","volume":"49","author":"Alvarez","year":"2013"},{"key":"ref12","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996"},{"key":"ref13","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00295.x","article-title":"Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma","volume":"10","author":"Saba","year":"2012"},{"key":"ref14","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1939-1676.2010.0588.x","article-title":"Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma","volume":"24","author":"Rassnick","year":"2010"},{"key":"ref15","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007"},{"key":"ref16","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1476-5810.2006.00090.x","article-title":"Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998\u2013March 2005)","volume":"4","author":"Fidel","year":"2006"},{"key":"ref17","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0300985810389316","article-title":"Recommended guidelines for submission, trimming, margin evaluation, and reporting of tumor biopsy specimens in veterinary surgical pathology","volume":"48","author":"Kamstock","year":"2011"},{"key":"ref18","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0300985815593349","article-title":"Mitotic count and the field of view area: time to standardize","volume":"53","author":"Meuten","year":"2016"},{"key":"ref19","series-title":"Vet Comp Oncol","first-page":"417","article-title":"Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. v1.1","volume":"14","year":"2016"},{"key":"ref20","series-title":"J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.5326\/JAAHA-MS-6059","article-title":"Association between macroscopic appearance of liver lesions and liver histology in dogs with splenic hemangiosarcoma: 79 cases (2004\u20132009)","volume":"50","author":"Clendaniel","year":"2014"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/251\/5\/javma.251.5.559.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/251\/5\/javma.251.5.559.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/251\/5\/javma.251.5.559.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:56:58Z","timestamp":1741330618000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/251\/5\/javma.251.5.559.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":20,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2460\/javma.251.5.559","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,1]]}}}